News & Updates

Show Multimedia Only

Perioperative adebrelimab plus chemo: A new Tx option for resectable NSCLC?

12 May 2026 by

Perioperative adebrelimab plus chemotherapy improves event-free survival (EFS) and major pathological response (MPR) in individuals with resectable stage II/III non-small cell lung cancer (NSCLC) in an interim analysis.

Perioperative adebrelimab plus chemo: A new Tx option for resectable NSCLC?

12 May 2026

High-dose influenza vaccination reduces hospitalizations in older adults

12 May 2026 by

High-dose influenza vaccination is associated with a reduced risk of hospitalization for pneumonia or influenza in older adults, regardless of immunosuppression status, according to a prespecified pooled analysis of the FLUNITY-HD study presented at ESCMID Global 2026.

High-dose influenza vaccination reduces hospitalizations in older adults

12 May 2026

Nitrofurantoin prevails in antibiotic showdown for uncomplicated UTI in women

11 May 2026 by

Nitrofurantoin performs better than single-dose fosfomycin in the treatment of uncomplicated urinary tract infections (UTIs) in women in the primary care setting, according to the SCOUT trial.

Nitrofurantoin prevails in antibiotic showdown for uncomplicated UTI in women

11 May 2026

Immunotherapy improves survival in ES-SCLC in first-line setting

11 May 2026

First-line treatment with immune checkpoint inhibitors (ICIs) is safe and effective in patients with extended stage (ES) small-cell lung cancer (SCLC), but its use as second-line agent is not recommended, according to a study.

Immunotherapy improves survival in ES-SCLC in first-line setting

11 May 2026

Tebentafusp a ray of hope in rare eye cancer

11 May 2026 by

The 5-year data from the phase III IMCgp100-202 study demonstrate durable, long-term overall survival (OS) benefit with the novel agent tebentafusp—a first-in-class, bispecific, soluble T-cell receptor (TCR) therapeutic—in individuals with previously untreated metastatic uveal melanoma (UM).

Tebentafusp a ray of hope in rare eye cancer

11 May 2026

Original New Drug Application Approvals by US FDA (16-30 April 2026)

11 May 2026

New drug applications approved by US FDA as of 16-30 April 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 April 2026)

11 May 2026

Seladelpar delivers improvements in cholestatic biomarkers, pruritus in PBC patients

09 May 2026 by

Treatment with seladelpar for up to 2 years improves cholestatic biomarkers and pruritus in patients with primary biliary cholangitis (PBC), with no serious safety concerns noted with long-term use, as shown by interim results of the ASSURE study.

Seladelpar delivers improvements in cholestatic biomarkers, pruritus in PBC patients

09 May 2026

Vixarelimab beneficial in prurigo nodularis

09 May 2026

Treatment with vixarelimab yields clinically meaningful improvements in prurigo nodularis (PN) symptoms, while having a favourable safety profile, according to a phase 2b study.

Vixarelimab beneficial in prurigo nodularis

09 May 2026

Naltrexone–bupropion a safe weight-loss treatment for persons with obesity, depression

08 May 2026 by

The extended-release combination of naltrexone and bupropion (NB-ER) may be used as safe and effective treatment for weight reduction among individuals with overweight/obesity and mild to moderate symptoms of depression, suggests a study.

Naltrexone–bupropion a safe weight-loss treatment for persons with obesity, depression

08 May 2026

Vemircopan holds little benefit in generalized myasthenia gravis

08 May 2026

The oral, selective factor D inhibitor vemircopan falls short of meeting the prespecified threshold for efficacy in the treatment of generalized myasthenia gravis, as shown in a phase 2 trial.

Vemircopan holds little benefit in generalized myasthenia gravis

08 May 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Perioperative adebrelimab plus chemo: A new Tx option for resectable NSCLC?

Perioperative adebrelimab plus chemo: A new Tx option for resectable NSCLC?

High-dose influenza vaccination reduces hospitalizations in older adults

High-dose influenza vaccination reduces hospitalizations in older adults

Nitrofurantoin prevails in antibiotic showdown for uncomplicated UTI in women

Nitrofurantoin prevails in antibiotic showdown for uncomplicated UTI in women

Immunotherapy improves survival in ES-SCLC in first-line setting

Immunotherapy improves survival in ES-SCLC in first-line setting

Tebentafusp a ray of hope in rare eye cancer

Tebentafusp a ray of hope in rare eye cancer

Original New Drug Application Approvals by US FDA (16-30 April 2026)

Original New Drug Application Approvals by US FDA (16-30 April 2026)

Seladelpar delivers improvements in cholestatic biomarkers, pruritus in PBC patients

Seladelpar delivers improvements in cholestatic biomarkers, pruritus in PBC patients

Vixarelimab beneficial in prurigo nodularis

Vixarelimab beneficial in prurigo nodularis

Naltrexone–bupropion a safe weight-loss treatment for persons with obesity, depression

Naltrexone–bupropion a safe weight-loss treatment for persons with obesity, depression

Vemircopan holds little benefit in generalized myasthenia gravis

Vemircopan holds little benefit in generalized myasthenia gravis